NCT05746689 is a NA clinical trial of Sirolimus in IgG4-related Disease, sponsored by Peking University International Hospital.

Who is sponsoring NCT05746689?

NCT05746689 is sponsored by Peking University International Hospital.

What drugs are being tested in NCT05746689?

Interventions in NCT05746689: Sirolimus.

What condition does NCT05746689 study?

NCT05746689 studies IgG4-related Disease.

Is NCT05746689 still recruiting?

NCT05746689 is currently not yet recruiting. Last updated 28 February 2023.

Last reviewed 2023-02-28 · How we verify

NCT05746689

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Sirolimus in IgG4-related Disease

Not yet recruiting NA Last updated 28 February 2023

What this trial tests

NA trial testing Sirolimus in IgG4-related Disease in 20 participants. Not yet recruiting.

Timeline

1 March 2023

Primary endpoint
31 December 2026

31 December 2028

Quick facts

Lead sponsor	Peking University International Hospital
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 March 2023
Primary completion	31 December 2026
Estimated completion	31 December 2028

Drugs / interventions tested

Sirolimus (sirolimus) — full drug profile →

Conditions studied

IgG4-related Disease — all drugs for IgG4-related Disease →

Sponsor

Peking University International Hospital

Who can join

Adults 18 to 80, any sex, with IgG4-related Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

gG4-related disease (IgG4-RD) is a newly recognized systemic autoimmune disease that can involve the pan-creatobiliary tract, retroperitoneum/aorta, head and neck region, and salivary glands, et al. Glucocorticoids are the first-line agents for the treatment of IgG4-RD, however, in order to maintain long-term disease stability and avoid disease relapse, glucocorticoids maintenance therapy should last for a long period, which may induce various glucocorticoid-associated adverse reactions. Sirolimus plays dual roles in inhibiting lymphocyte activation and fibroblast proliferation. It is inferred from its mechanism that sirolimus is a good potential treatment option for IgG4-RD. Therefore, we conducted this single-arm clinical trial on patients with IgG4-RD to determine the efficacy and safety of sirolimus.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Current and future advances in practice: IgG4-related disease.
Wallace ZS, Katz G, Hernandez-Barco YG, Baker MC. · · 2024 · cited 33× · PMID 38601138 · DOI 10.1093/rap/rkae020
IgG4-Related Disease: Emerging Roles of Novel Genetic Variants, Immune Cell Subsets and Therapeutic Targets.
Tedesco L, Ali SB, Erman B, Baris S, et al · · 2025 · cited 1× · PMID 40785550 · DOI 10.1111/all.16686
Immunocyte lipid metabolic reprogramming: a novel pathway for targeted intervention in autoimmune diseases.
Cui Y, Feng Z, Zhao Q, Dai H, et al · · 2025 · PMID 41280910 · DOI 10.3389/fimmu.2025.1713148

Verify or expand the search:

Other trials of Sirolimus

Trials testing the same drug.

NCT07542314 — Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a · Phase 4 · not yet recruiting
NCT06876142 — Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma · Phase 1, PHASE2 · suspended
NCT07052929 — Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need Ventilators · Phase 1, PHASE2 · recruiting
NCT04370795 — Matched Related and Unrelated Donor Stem Cell Transplantation for Severe Combined Immune Deficiency (SCID): Busulfan-bas · Phase 1, PHASE2 · withdrawn
NCT07162038 — Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA- · Phase 1 · recruiting

Other recruiting trials for IgG4-related Disease

Currently open trials in the same condition.

NCT07025330 — A Study of Efgartigimod in Patients With IgG4-Related Disease · Phase 2 · recruiting
NCT06663618 — Short-term Glucocorticoid Combined with MMF for IgG4-RD · NA · recruiting

Other Peking University International Hospital trials

Trials by the same sponsor.

NCT05844813 — Neoadjuvant Chemotherapy Combined With Targeted Treatment in High-risk Retroperitoneal Sarcoma · Phase 4 · enrolling by invitation
NCT03516851 — Precision Bypass in Patients With Moyamoya Disease · NA · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05746689 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University International Hospital
Last refreshed: 28 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05746689.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing